News & Events


RareCyte Completes $30M Private Financing for Commercial Expansion of Rare Cell Detection Technology for Liquid Biopsies

Seattle, WA, August 24, 2017 – RareCyte, Inc., a global rare cell detection and liquid biopsy company will use the funding to advance its commercial sales efforts and build companion diagnostics (CDx) programs with strategic partners. The company will also expand its regulatory infrastructure and research and development efforts. The $30M investment was led by 5AM Ventures with participation from existing investors Telegraph Hill Partners (THP), founder Ron Seubert and other investors.


RareCyte introduces the CyteFinder® HT instrument at AACR for high throughput slide-based imaging optimized for single cell Liquid Biopsy

Seattle, WA, April 16, 2018 – RareCyte, Inc., a global rare cell detection and liquid biopsy company announces its newest product, CyteFinder HT in conjunction with the American Association for Cancer Research (AACR) Annual Meeting in Chicago April 15 through 18. CyteFinder HT, RareCyte’s newest member of the CyteFinder family enables high-speed whole slide imaging with up to six channels specifically designed for the needs of high throughput liquid biopsy applications. The CyteFinder HT incorporates slide cassettes for unattended imaging of up to 80 slides and enables processing of up to 120 slides in 24 hours for cells, blood smears, or tissue samples.



Genitourinary Cancers Symposium

February 14-16, 2019
San Francisco, CA
Booth #60

Molecular Med TRI-CON

March 10-15, 2019
San Francisco, CA
Booth #701